|
DEBUT ISSUE - October 2001 (v00-n00) |
|
- Main Story - pgs. 1-23 Titan Pharmaceuticals (AMEX:TTP)
- Macro Market Commentary - pg. 24
- News Briefs - pgs. 25-26
- NIBM Model Portfolio & Updates - pgs. 27-30
|
 |
|
| This month's Main Story is on the diversified
biotech company Titan Pharmaceuticals. With drugs addressing oncology and central nervous
system disorders, the company has an attractive and deep pipeline. Their major problem is
management does not seem to be willing to ever advance development of a pipeline drug
unless they can find someone else to pay for it. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story
- Summary
- Cash Position
- Table - Basic Facts
- Table - Product Pipeline
- Product Pipeline
- Business Model
- Investment Case
- Disclosure
- Iloperidone
- Table - Iloperidone indications and trials
- Table - Worldwide antipsychotic market
- Traditional antipsychotics
- Atypical antipsychotics
- The Phase III studies
- Table: Competitive landscape for atypical antipsychotics
- A problem
- New pivotal studies
- Table: new iloperidone pivotal trials
- Iloperidone going forward
- Spheramine
- Table: Spheramine descriptions
- Table: Parkinson's disease statistics
- Table: Commercial Parkinson's treatment statistics
- Cell implantation therapies
- Table: Comparison of cell implantation therapies
- Human fetal cells
- Porcine fetal cells (Diacrin)
- Human retinal pigment epithelial cells (Spheramine)
- Concluding comments
- Cancer Products
- Table - Potential market for Titan products
- Sidebar: Caveats for sizing potential markets
- Cancer Immunotherapy
- Sidebar: Immune system components
- Titan's cancer vaccines
- Sidebar: Lung cancer defined
- Competitive landscape
- Table: Titan's competitive landscape
- CeaVac
- Table: CeaVac details
- TriAb
- Table: TriAb details
- TriAb + CeaVac
- Table: TriAb + CeaVac details
- Table Potential market indications
- TriGem
- Table: TriGem details
- Small molecule cancer drugs
- Pivanex
- Table: Pivanex details
- Early results point to clinical promise
- Table: Other companies targeting bcl-2
- Gallium Maltolate
- Table: Gallium maltolate details
- Table: IV gallium versus gallium maltolate
- Preclinical Products
- RB94
- Table: RB94 details
- ProNeura drug delivery system
- Table: ProNeura details
- Summary
- Table: Important investor milestones
-
- What Can Go Wrong
- Macro Market Commentary
- News Briefs
- Market reaction to coated stent trial might energize device
sector
- AAV vector tenuously linked to cancer in mice
- Imclone/Bristol pact might reboot biotech funding
- NIBM Model Portfolio and Updates
- Introducing the Model Portfolio members
- Performance data
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
